reports
Notice to Convene the Annual General Meeting of Genmab A/S
Notice to Convene the Annual General Meeting of Genmab A/S Company Announcement Genmab A/S to hold Annual General Meeting on Thursday March 19, 2026 COPENHAGEN, Denmark; February 18, 2026 – (Nasdaq: GMAB) summons the Annual General Meeting on Thursday, March 19, 2026, at 2:00 PM CET at the Copenhagen Marriott Hotel, Kalvebod Brygge 5, DK-1560 Copenhagen V, Denmark. The notice for the Annual General Meeting, including Appendix 1: Candidates for the Board of Directors, is attached. About Genmab Genmab is an international biotechnology company dedicated to improving the lives of people ...
- ABGSC Financials Research
- Fredrik Flørnes Støle
- Patrik Brattelius
- Simon Brun
Genmab Announces Initiation of Share Buy-Back Program
Genmab Announces Initiation of Share Buy-Back Program Company Announcement Repurchase of up to 342,130 shares with a maximum aggregate total value of 725 million DKK Honoring our commitments under the Restricted Stock Unit programCompletion expected no later than March 31, 2026 COPENHAGEN, Denmark; February 17, 2026 – (Nasdaq: GMAB) announced today that it is initiating a share buy-back program, to honor our commitments under the Restricted Stock Unit program. The share buy-back program will be undertaken on the terms set out below and in accordance with Regulation (EU) No. 596/2014 (‘M...
- ABGSC Pulp & Paper Research
- Henrik Bartnes
- Martin Melbye
Genmab Files Annual Report with the U.S. Securities and Exchange Commi...
Genmab Files Annual Report with the U.S. Securities and Exchange Commission Media ReleaseCOPENHAGEN, Denmark; February 17, 2026 Genmab filed Form 20-F for the financial year 2025 with the U.S. SEC (Nasdaq: GMAB) announced today that it has filed its Annual Report for the financial year 2025 on Form 20-F with the U.S. Securities and Exchange Commission (SEC), incorporating by reference parts of the Genmab A/S Annual Report 2025. Both reports are available via the SEC’s website, and Genmab’s website, . About Genmab Genmab is an international biotechnology company dedicated to improving t...
Genmab Publishes 2025 Annual Report
Genmab Publishes 2025 Annual Report Company Announcement COPENHAGEN, Denmark; February 17, 2026 – (Nasdaq: GMAB) announced today the publication of its Annual Report for 2025. Below is a summary of business progress in 2025, financial performance for the year and the financial outlook for 2026. The full report is attached as a PDF file and in iXBRL format and can be found in the investor section of the company’s website, . Conference CallGenmab will hold a conference call to discuss the full year results for 2025 today, February 17, 2026 at 6:00 pm CET, 5:00 pm GMT, 12:00 pm EST. To join...
Essity Aktiebolag (publ): 1 director
A director at Essity Aktiebolag (publ) bought 1,000,000 shares at 261.568SEK and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last tw...
- ABGSC Financials Research
- Fredrik Flørnes Støle
- Simon Brun
Grant of Restricted Stock Units and Warrants to Employees in Genmab
Grant of Restricted Stock Units and Warrants to Employees in Genmab Company Announcement COPENHAGEN, Denmark; January 29, 2026 – (Nasdaq: GMAB) announced today that the Board of Directors decided to grant 32,806 restricted stock units and 34,307 warrants to employees of the Company and the Company's subsidiaries. Each restricted stock unit is awarded cost-free and provides the owner with a conditional right to receive one share in Genmab A/S of nominally DKK 1. The fair value of each restricted stock unit is equal to the closing market price on the date of grant of one Genmab A/S share, ...
- ABGSC Financials Research
- Fredrik Flørnes Støle
- Simon Brun
- ABGSC Financials Research
- Fredrik Flørnes Støle
- Simon Brun
- ABGSC Pulp & Paper Research
- Henrik Bartnes
- Martin Melbye
- ABGSC Pulp & Paper Research
- Henrik Bartnes
- Martin Melbye
- ABGSC Financials Research
- Fredrik Flørnes Støle
- Simon Brun
Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2025
Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2025 Company Announcement Net sales of DARZALEX® in 2025 totaled USD 14,351 millionGenmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc.) COPENHAGEN, Denmark; January 21, 2026 – (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX® (daratumumab), including sales of the subcutaneous (SC) product (daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX FASPRO® in the U.S.), as reported by J&J were USD 14,351 million in 2025. Net trade sale...
Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) f...
Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Company Announcement Based on the topline results from the EPCORE® DLBCL-1 trial, Genmab will engage global regulatory authorities to discuss next steps COPENHAGEN, Denmark; January 16, 2026 – (Nasdaq: GMAB) today announced topline results from the Phase 3 EPCORE DLBCL-1 trial evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, which demonstrated an improvement in progress...
- ABGSC Pulp & Paper Research
- Henrik Bartnes
- Martin Melbye
- ABGSC Pulp & Paper Research
- Henrik Bartnes
- Martin Melbye
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.